MREO

Business Context and Reporting Period

Mereo Biopharma Group Plc (Nasdaq: MREO) is a U.K.-based biopharmaceutical company focused on developing therapeutics for rare diseases. The company operates as a single segment and is currently in the clinical development phase with no approved products or product sales revenue. Key product candidates include setrusumab for osteogenesis imperfecta (OI) and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). This summary covers the quarterly period ended March 31, 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $6.2 million (48%) compared to Q1 2025, primarily driven by a significant reduction in G&A expenses and a favorable foreign currency transaction gain.
• Foreign Currency Impact: The company recorded a $1.6 million foreign currency transaction gain in Q1 2026, compared to a $2.8 million loss in Q1 2025, due to the strengthening of the U.S. dollar against the pound sterling.
• R&D Expenses: R&D expenses increased by $0.8 million. This was driven by a $2.3 million charge related to the cancellation of manufacturing slots by partner Ultragenyx for setrusumab, partially offset by reduced spending on alvelestat following the completion of Phase 3 preparation activities.
• G&A Expenses: G&A expenses decreased by $3.3 million. Key drivers included a $1.9 million reimbursement from the depository for ADR program expenses and a $1.4 million reduction in pre-commercial investment activities.
• Liquidity: Cash and cash equivalents decreased by $4.6 million during the quarter, resulting in a balance of $36.2 million as of March 31, 2026.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects current cash resources to fund operations and capital expenditure requirements into mid-2027. The company anticipates needing additional external funding to complete development plans and potential commercialization.
• Legal Proceedings: A putative securities class action lawsuit (Dodge v. Mereo Biopharma Group PLC) was filed on February 4, 2026, alleging false and misleading statements regarding the company's business. The company intends to vigorously defend the action but cannot currently estimate potential losses.
• Commitments: The company has contingent obligations under agreements with Novartis and AstraZeneca, including potential milestone payments and royalties based on future commercial sales. Additionally, a manufacturing agreement with Ultragenyx involves reimbursement for process development and supply costs.
• Risk Factors: Key risks include the uncertainties of clinical development, reliance on third-party partners for trials and funding, regulatory approval uncertainties, and the need to raise additional capital on favorable terms.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $36.2 million cash balance to sustain operations through mid-2027 given the burn rate and potential for increased R&D spend.
• Setrusumab Manufacturing: Review the implications of the $2.3 million charge for cancelled manufacturing slots with Ultragenyx and the status of future supply agreements.
• Legal Exposure: Monitor the progress of the putative securities class action filed in February 2026 and any potential financial impact.
• Foreign Exchange Sensitivity: Assess the volatility of the company's financial results due to the translation of U.S. dollar balances into its functional currency (pound sterling).
• Future Funding Needs: Evaluate the company's strategy for raising additional capital, including potential dilution from equity offerings or terms of debt financing.